Seventh Wave and TNO announce GI modelling pact at AAPS
Seventh Wave Laboratories will apply gastrointestinal modelling to the analysis of early stage drug candidates being developed by its customers.
The deal, unveiled at AAPS 2009 in Los Angeles, will see Dutch contract research organisation (CRO) TNO supply Seventh Wave with its TIM range of gastrointestinal models to help the latter’s clients assess the behaviour of oral medications.
According to TNO the new contract offering, which will operate out of Seventh Wave’s facility in Chesterfield, Missouri, will cut research timelines for preclinical drug development when it becomes operational in 2010.
Seventh Wave CEO John Sagartz said that: “With the TIM system available on site, we have another valuable tool to solve our customers’ specific needs in formulation development and pharmakokinetics.”
